Incretin-based therapies such as DPP-4 inhibitors have demonstrated the ability to potentiate GABAergic, dopaminergic, serotonergic, and noradrenergic neurotransmission, which are crucial pathways for awakening drugs in both coma and prolonged DOC (see Introduction). The gene discussed is DPP4; the disease is Coma.